Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States
PSMA-PET was rapidly incorporated into clinical practice among commercial insurance beneficiaries with prostate cancer with higher adoption in geographic regions with higher income and education.
Authors
- Aaron Philip Mitchell (ORCID: https://orcid.org/0000-0003-3639-3515)
- Jianjin Xu (ORCID: https://orcid.org/0000-0001-9312-6339)
- Maximilian Rabil (ORCID: https://orcid.org/0000-0002-2314-0802)
- Lawrence Saperstein
- Daniel L. Suzman (ORCID: https://orcid.org/0000-0002-1702-6114)
- S Wang
- Catherine Lerro
- Cary P. Gross (ORCID: https://orcid.org/0000-0002-4974-935X)
- Preston C. Sprenkle (ORCID: https://orcid.org/0000-0003-0502-9294)
- Xiaomei Ma (ORCID: https://orcid.org/0000-0001-9472-8032)
- Gabriela Spilberg
- Donna R. Rivera
- Jaleh Fallah
- Paul G. Kluetz
- Michael S. Leapman
- Sarah Westvold
- R. Jeffrey Karnes
- Michaela Dinan
- Natalia Kunst
- Isaac Y. Kim
Institutions
- United States Food and Drug Administration (US)
- Center for Drug Evaluation and Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale Cancer Center (US)
- Yale University (US)
- Mayo Clinic in Arizona (US)
- University of York (GB)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1200/op-25-00617
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00